You may be able to reduce tardive dyskinesia with treatment. Some lifestyle behaviors, like getting enough sleep and exercise, can help. Tardive dyskinesia is a side effect of neuroleptic or ...

Tardive dyskinesia is a medication-induced movement disorder that causes uncontrollable muscle movements in the face, neck, and limbs. Symptoms may continue even after stopping the medication. Tardive ...

Tardive dyskinesia causes involuntary movements in some people taking antipsychotic medications. Here’s what you need to know about this movement disorder. Antipsychotic medications are a mainstay of ...

Credit: Getty Images This patient fact sheet describes the medications that are known to induce tardive dyskinesia, its symptoms, and ways in which the disease state may be managed. Our easy-to-read ...

While any patients taking an anti-dopaminergic agent may develop tardive dyskinesia (TD) -- a movement disorder hallmarked by abnormal and involuntary tics of the face, trunk, and limbs -- older ...

Some studies suggest vitamin E may help ease symptoms of tardive dyskinesia — but how strong is the evidence, and what does it really tell us? Note: The U.S. Food and Drug Administration (FDA) does ...

Tardive dyskinesia is a common side effect caused by antipsychotic use. It is a neurological disorder characterized by involuntary, repetitive movements, often involving the face, mouth, tongue, and ...

—The exact pathology of tardive dyskinesia is still unclear, but the potential genetic factors these investigators have identified may enhance the understanding, treatment, and prevention of this ...

A case report indicates that valbenazine may be an effective therapy for chorea-ballism associated with tardive dyskinesia. Valbenazine has therapeutic potential to improve chorea-ballism associated ...

Kristin Weiland is a documentary film producer and writer with a background in crisis management and ethnographic research. She specializes in investigative and social impact documentary projects, and ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has confirmed its initial recommendation to not consider deutetrabenazine as a new active substance. In June this ...